Minapharm Pharmaceuticals (CAI:MIPH) Total Debt per Share: E£367.67 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:MIPH Minapharm Pharmaceuticals CAI:MIPH
49 GF Score
Price E£790.19
GF Value E£369.13
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Minapharm Pharmaceuticals Total Debt per Share?

Minapharm Pharmaceuticals CAI:MIPH +3.59% 49 Total Debt per Share is E£367.67 as of Dec. 2025. GuruFocus rates CAI:MIPH with a GF Score™ of 49/100 and a GF Value™ of E£369.13 (Significantly Overvalued). The stock has 10 warning signs investors should review.

E£367.67 (As of Dec. 2025)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Minapharm Pharmaceuticals's Total Debt Per Share for the quarter that ended in Dec. 2025 was E£367.67.

Minapharm Pharmaceuticals Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Minapharm Pharmaceuticals's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minapharm Pharmaceuticals Total Debt per Share Chart

Minapharm Pharmaceuticals Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Debt per Share
100.44 196.45 307.38 443.88 367.67

Minapharm Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 443.88 445.04 455.75 440.33 367.67
CAI:MIPH
49GF Score
Minapharm Pharmaceuticals CAI:MIPH
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minapharm Pharmaceuticals Total Debt per Share Calculation

Minapharm Pharmaceuticals's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(1,763+2,757)/12
=367.67

Minapharm Pharmaceuticals's Total Debt Per Share for the quarter that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(1,763+2,757)/12
=367.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of E£367.67 mean?
Minapharm Pharmaceuticals (CAI:MIPH) has a Total Debt per Share of E£367.67 as of Dec. 2025. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Minapharm Pharmaceuticals and its competitors.
Is Minapharm Pharmaceuticals' Total Debt per Share too high?
Minapharm Pharmaceuticals' current Total Debt per Share is E£367.67. Overall, Minapharm Pharmaceuticals has a GF Score™ of 49/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Minapharm Pharmaceuticals' Total Debt per Share compare to ZTS and UTHR?
Minapharm Pharmaceuticals' Total Debt per Share of E£367.67 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Drug Manufacturers company?
A good Total Debt per Share depends on the Drug Manufacturers industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Minapharm Pharmaceuticals and its competitors. Minapharm Pharmaceuticals's current Total Debt per Share is E£367.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minapharm Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Minapharm Pharmaceuticals (CAI:MIPH) is currently considered Significantly Overvalued. The stock's GF Value™ is E£369.13, compared to a current price of E£790.19 — trading 114.1% above its estimated fair value. The current Total Debt per Share is E£367.67. Minapharm Pharmaceuticals' overall GF Score™ is 49/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Minapharm Pharmaceuticals (CAI:MIPH), the current Total Debt per Share is E£367.67 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Minapharm Pharmaceuticals (CAI:MIPH) Overvalued in 2026?

Based on GuruFocus' analysis, Minapharm Pharmaceuticals stock appears to be overvalued. The current stock price of E£790.19 is trading 114.1% above its estimated GF Value™ of E£369.13. GuruFocus considers Minapharm Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for CAI:MIPH:

  • Total Debt per Share: E£367.67
  • GF Value™: E£369.13 vs. price of E£790.19 (114.1% above fair value)
  • GF Score™: 49/100 with 10 warning signs

No single metric tells the full story. See the CAI:MIPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Minapharm Pharmaceuticals Business Description

Address El-Bardissi Street, 2T Takseem Asmaa Fahmy Street, Heliopolis, Cairo, EGY
Minapharm Pharmaceuticals is a company whose purpose is to produce medicines and chemicals. medical supplies. cosmetics, veterinary medicines, dental supplies, and the production of dietary supplements and herbal medicines. It produces drugs for many segments such as biogenetics, orthopedic, ophthalmology, miscellaneous, dermatology, gastroenterology, cardiology, and uro-gynaecology lines.
49GF Score

Get the complete analysis for CAI:MIPH

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£790.19
Price
E£369.13
GF Value